Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
Climacteric : the Journal of the International Menopause Society|October 6, 2012
Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal womenH Yu, J Racketa, A A Chines, et al.
Statistical Methods in Medical Research|September 13, 2012
A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass densityJ Detilleux, J-Y Reginster, A Chines, et al.
Menopause (New York, N.Y.)|May 2, 2013
Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogensJohn Christopher Gallagher, Harry Shi, Sebastian Mirkin, et al.
Calcified Tissue International|October 13, 2004
Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosisL-G Ste-Marie, E Sod, T Johnson, et al.
The Journal of Clinical Endocrinology and Metabolism|March 1, 1991
Subclinical vitamin D deficiency in postmenopausal women with low vertebral bone massD T Villareal, R Civitelli, A Chines, et al.
Climacteric : the Journal of the International Menopause Society|October 9, 2012
Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal womenS Mirkin, B S Komm, K Pan, et al.
The Journal of Pediatrics|July 1, 1991
Hypercalciuria in children severely affected with osteogenesis imperfectaA Chines, D J Petersen, F W Schranck, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|April 19, 2013
An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®J-M Kaufman, S Palacios, S Silverman, et al.
Bone|December 13, 2002
Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosisE F Eriksen, F Melsen, E Sod, et al.
Calcified Tissue International|December 4, 2001
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapyD M Reid, S Adami, J P Devogelaer, et al.
Pageof 7